Effectiveness After Four and Twentyfour Weeks and Safety of Tocilizumab in Patients With Active RA.

Trial Profile

Effectiveness After Four and Twentyfour Weeks and Safety of Tocilizumab in Patients With Active RA.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 18 Dec 2009 Actual patient number (332) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top